AHB takes celadrin into Central and South America

- Last updated on GMT

Related tags: Clinical trial, Placebo

Dallas, Texas based Mosaic Nutraceuticals announced yesterday it
has appointed AHB Trading as the distributor for its products in
Mexico, Central and South America.

Mosaic said it expects to start shipping orders of its flagship products Celaprix and Lipotrene to AHB within the next 45 days.

"We believe our products are appealing to consumers in the regions that AHB covers and that if AHB meets its initial sales projections for Celaprix and Lipotrene we should see a substantial increase in our shareholder value in the near future,"​ said Charles Townsend, the president of Mosaic Nutracueticals​.

The company noted that Celaprix is a topical rub that is said to reduce pain and help reverse the effects of osteoarthritis. The product is made primarily from a combination of celadrin and boswellian extract.

Celadrin is a natural compound made up of of esterified fatty acid carbons (EFACs) and other active synergists, and can be formulated into pill and cream forms.

Results of a clinical trial, published in the Journal of Rheumatology two years ago, suggested that Celadrin could help with joint and mobility problems.

The double-blind, multi-centre, placebo-controlled trial examined the impact of a 68-day oral administration of Celadrin on 64 participants who were experiencing joint and mobility problems.

The researchers reported that after the trial period, participants who consumed Celadrin showed healthy joint mobility, flexibility and function compared to those given the placebo.

Data from the study also indicated that Celadrin not only promoted joint flexibility, but also supported and promoted the ability to walk long distances.

According to the Centers for Disease Control and Prevention (CDC), arthritis and other rheumatic conditions are among the most common chronic diseases, affecting 70 million adults in the US in 2001, and are the leading cause of disability among US adults.

Research by the CDC has shown that if arthritis prevalence rates remain stable, the number of affected persons aged 65 and under will nearly double by 2030, meaning that as many as 41 million people in this age group could be afflicted by arthritis or chronic joint symptoms (CJS).

Lipotrene, on the other hand, is a cholesterol chew that the company claim has been shown in clinical studies to reduce cholesterol levels naturally by as much as 20 percent.

Mosaic estimates that $30 billion is spent annually on cholesterol lowering products.

Related topics: Suppliers

Follow us


View more